Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
HRYZ Biotech Co.
Modality
Cell therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05787535CT.gov HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Oropharyngeal Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Hryz-T101 Tcr-T Cell (this asset) | HRYZ Biotech Co. | P1 | CC · 43 |
| Cyclophosphamide | HRYZ Biotech Co. | P2 | BB |
| Fludarabine | HRYZ Biotech Co. | P2 | BB |
| Cis-Diamminedichloroplatinum Ii | Loren Mell, MD | P2 | B |
| Pembrolizumab | Inhibrx Biosciences, Inc | P2 | B |
| Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap | National Cancer Institute (NCI) | P2 | B |
| Young Til | National Cancer Institute (NCI) | P2 | B |
| Ipilimumab | National Cancer Institute (NCI) | P2 | CCC |
| Nivolumab | National Cancer Institute (NCI) | P2 | CCC |
+15 more in the Oropharyngeal Carcinoma cohort
Other indications for Hryz-T101 Tcr-T Cell
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Vaginal Neoplasm | — | P1 | CC · 43 |
| Penile Carcinoma | — | P1 | CC · 43 |
| Anal Carcinoma | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- CyclophosphamideHRYZ Biotech Co.BB
- FludarabineHRYZ Biotech Co.BB
- Cis-Diamminedichloroplatinum IiLoren Mell, MDB
- PembrolizumabInhibrx Biosciences, IncB
- Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. TrapNational Cancer Institute (NCI)B
Citation
Floatz Terminal. Hryz-T101 Tcr-T Cell in Oropharyngeal Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/hryz-t101-tcr-t-cell-oropharyngeal-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →